Educational Webinars
Upcoming Webinars:
In this webinar we'll cover:
The evolving AI landscape in pharma and medical affairs
Inside the AI toolbox: what’s possible (and what’s not)
Real-world case studies of AI solutions in pharma
Open Q&A and discussion
In this webinar we'll cover:
A clear, non-technical explanation of agents, how they differ from “just ChatGPT”, and where they fit in your current commercial tools and processes.
A focused tour of high-impact use cases already feasible in pharma today: brand planning, content support and document retrieval, field coaching, and insight generation.
How to choose a strong first use case, map the workflow, define the system prompt and the knowledge base, turning a business problem into a working agent without overcomplicating things.
Open Q&A
In this webinar we'll cover:
The shifts in HCP behaviour that explain declining attention and content fatigue
How to adopt a trust-based, inbound content model tailored for HCP needs
What “discoverability” means today, including the role of search and AI tools
Real-world examples of educational content that supports HCPs at the moment of need
In this webinar we'll cover:
How AI is being applied — unevenly but increasingly — across BD workflows
Practical AI use cases for in-licensing: search, monitoring, due diligence
How AI can support out-licensing: partner identification, conference prep, negotiation readiness
Examples of tools and approaches BD teams are trying today
Key risks, limitations and common pitfalls
In this webinar we'll cover:
Why AI cannot escape the need for value-for-money evidence
How AI’s impact can be evaluated through the “quintuple aim” framework (patient outcomes, patient experience, clinician well-being, cost, and equity)
How to assess value for money — and how these methods apply to AI
What recent systematic reviews reveal about the cost-effectiveness of AI in healthcare
Common shortcomings in current economic evaluations of AI solutions
Why a full Health Technology Assessment of AI in healthcare is needed
Recorded Webinars:
In this webinar you will learn:
How a “perfect” payer/prescriber interview should unfold, and why most interviews never achieve this.
The evidence, through actual AI vs human case studies, that shows how AI-moderated interviews can significantly outperform human moderators.
Outperformance means more insights and deeper insights that are measurable.
The psychology of why human respondents give more depth and more honesty when talking to an AI moderator.
What this means for the future of your pharma payer and prescriber research.
In this webinar you will learn:
What is the biggest challenge faced by Medical Affairs?
What is driving the evolution of Medical Affairs and how does it affect us?
What are the key ambitions for Medical Affairs and what is its role in modern pharma?
How can this roadmap help to develop a positive culture of Medical Affairs Excellence?
In this webinar you will learn:
Where and how AI can be integrated in the market access process
How AI-based tools can reduce time and resource demands in dossier writing
What HTA bodies and payers really accept when it comes to AI-supported evidence
Live demonstration of use cases in pricing, objection handling, and launch planning
In this webinar you will learn:
What we mean by Medical Affairs impact: Defining and understanding the concept
The 5 pillars of Medical Affairs impact: A framework for driving success
Different perspectives on impact: Short-term vs. long-term, micro vs. macro, internal vs. external
Making your impact visible: Best practices for communicating value to internal stakeholders
In this webinar you will learn how to optimally:
Allocate resources in a country across brands in an agile way
Allocate resources across tactics at brand level, ex ante and ex post
In this webinar you will learn:
Simple alternatives to traditional conjoint methods that handle complex product profiles much more effectively
Alternative approaches that require smaller sample sizes
Leveraging the vast repository of over $50 million worth of published pharma conjoint studies
Why (unfortunately) you cannot survey ChatGPT instead of doing conjoints (Harvard academics have tried!)
In this webinar you will learn:
What is better and what is more accepted: comparative RWE versus indirect comparisons based on trials.
Synthetic control groups and post-approval comparative RWE studies: How do they work?
Existing guidance and guidelines for comparative RWE studies
In this webinar you will learn:
How to personalise portfolio strategy at a country level as a component of near-term portfolio planning
How to align investment priorities when considering mid-term portfolio strategy
How to manage uncertainty in the context of portfolio planning for the long term
In this webinar you will learn:
Overview of the pharmaceutical value chain, a simple but powerful framework
How BD&L activities help leverage strengths and address weaknesses across the full value chain
Application of the value chain framework to assess strengths and weaknesses at each stage of the BD&L process
In this webinar you will learn:
Using AI and/or econometrics to analyse past payer behaviour. Because, for payers, sometimes “actions speak louder than words”.
Using meta-analysis to uncover powerful predictions from the mountain of published research papers.
Using simulators of “virtual negotiations” to understand innovative contracting schemes from your and payers’ perspectives.
In this webinar you will learn:
How to talk about value for money to clinicians and patient advocacy groups
How to align the clinical and the health economic view
How to go beyond the QALY to account for what matters to patients
How to deal with evidence gaps: the increasing role of Real World Evidence
In this webinar you will learn:
The key ways that cell and gene therapy do and do not differ from more “conventional” therapies.
The commercial significance of the fact that cell and gene therapies invariably enter the market with “one foot still in the lab” (i.e. with immature clinical data).
The vital importance of “hope-based therapy” (high levels of uncertainty) rather than “evidence-based therapy” and how customers (payers/prescribers) actually act when faced with these uncertainties.
...
In this webinar you will learn:
The state of the art for measuring QALYs
The value of a QALY
Measuring health gains: beyond the QALY